Dova receives European marketing authorization

Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort. The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease. The company's stock was up almost 10 percent Wednesday following…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news